NASDAQ
17.10.25 | 21:59
2,375 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | C4 Therapeutics prices $125M equity offering with warrants | 5 | Seeking Alpha | ||
| Do | C4 Therapeutics, Inc.: C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering | 4 | GlobeNewswire (USA) | ||
| Do | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.10. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma | 104 | GlobeNewswire (Europe) | WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 01.10. | C4 Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 23.09. | C4 Therapeutics stock price target raised to $10 by Wells Fargo on positive data | 10 | Investing.com | ||
| 23.09. | C4 Therapeutics: Wells Fargo verdoppelt Kursziel nach positiven Studiendaten | 5 | Investing.com Deutsch | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 22.09. | Forecasting The Future: 4 Analyst Projections For C4 Therapeutics | 3 | Benzinga.com | ||
| 22.09. | C4 Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.09. | Myelom-Medikament von C4 Therapeutics zeigt 50-prozentige Ansprechrate in Studie | 1 | Investing.com Deutsch | ||
| 20.09. | C4 Therapeutics Reports Promising Phase 1 Results For Cemsidomide In R/R Multiple Myeloma | 1 | RTTNews | ||
| 20.09. | C4 Therapeutics' myeloma drug shows 50% response rate in trial | 2 | Investing.com | ||
| 20.09. | C4 Therapeutics, Inc.: C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 16.09. | Barclays bestätigt "Overweight"-Rating für C4 Therapeutics | 1 | Investing.com Deutsch | ||
| 16.09. | C4 Therapeutics stock rating reiterated as Overweight by Barclays | 3 | Investing.com | ||
| 16.09. | Why C4 Therapeutics Stock Crushed the Market on Monday | 3 | The Motley Fool | ||
| 15.09. | Stephens-Upgrade beflügelt C4 Therapeutics-Aktie mit über 125 % Kurspotenzial | 5 | Investing.com Deutsch | ||
| 15.09. | C4 Therapeutics stock surges after Stephens upgrade signals upside | 4 | Investing.com | ||
| 04.09. | C4 Therapeutics, Inc.: C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration | 293 | GlobeNewswire (Europe) | WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science... ► Artikel lesen | |
| 04.09. | C4 Therapeutics stock initiated with Buy rating at Guggenheim on myeloma drug potential | 2 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INOVIO PHARMACEUTICALS | 2,020 | -0,98 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan | PLYMOUTH MEETING, Pa., Oct. 2, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,407 | +2,89 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,900 | +0,96 % | Cardiff Oncology nach Daten-Dip: Jetzt kaufen? | Cardiff Oncology legt seine lang erwarteten Krebs-Daten vor und der Aktienkurs fährt Achterbahn: Bietet sich für Anleger ein neues Trading-Fenster, oder lässt man jetzt besser die Finger von dem Titel?... ► Artikel lesen | |
| CELLDEX THERAPEUTICS | 23,600 | +2,61 % | Analyst Expectations For Celldex Therapeutics' Future | ||
| COHERUS ONCOLOGY | 1,397 | -0,96 % | Coherus Oncology: Nach der Rallye folgt der Durchbruch? | Die Aktie von Coherus Oncology hat in den vergangenen Monaten deutlich an Dynamik gewonnen. Mit über 60 Prozent Kursplus seit April 2025 rückt das Unternehmen ins Rampenlicht - getragen von wachsenden... ► Artikel lesen | |
| NEOVACS | 0,273 | +170,83 % | XFRA NEW INSTRUMENTS AVAILABLE ON 18.07.2025 |
The following instruments on XETRA do have their first trading 18.07.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 18.07.2025
Aktien
1 KYG7388C1033 Qunabox Group Ltd.
2... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,660 | 0,00 % | Arcturus Therapeutics Holdings Inc. - 8-K, Current Report | ||
| ULTRAGENYX | 27,800 | -0,71 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NOVATO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for... ► Artikel lesen | |
| GYRE THERAPEUTICS | 7,100 | -0,70 % | Gyre Therapeutics Inc.: Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis | SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ... ► Artikel lesen | |
| BIOMEA FUSION | 1,505 | 0,00 % | H.C. Wainwright reiterates Buy rating on Biomea Fusion stock amid investor concerns | ||
| GOSSAMER BIO | 2,036 | +8,18 % | Respira Therapeutics, Inc.: Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital | - Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and... ► Artikel lesen | |
| JANUX THERAPEUTICS | 26,760 | 0,00 % | Janux Therapeutics: Günstige Gelegenheit | Janux Therapeutics hat mit seiner innovativen Plattformtechnologie im letzten Jahr das Interesse vieler Investoren geweckt - nicht zuletzt aufgrund von Übernahmegerüchten. Doch unabhängig von einem... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,100 | -3,17 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination | Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 9,840 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces New Employment Inducement Grants | ||
| TENAYA THERAPEUTICS | 1,810 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
Das Unternehmen C4 THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 2,375 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.